779 patents
Page 16 of 39
Utility
CD1a ANTIBODIES AND USES THEREOF
14 Apr 22
Antibodies, and antigen-binding fragments thereof, that specifically bind to Cluster of Differentiation 1a (CD1a) are provided.
Florian WINAU, Oleg V. KOVALENKO, Chew Shun CHANG, Di WU, Nicholas Andrew MARZE, Shian-Huey CHIANG
Filed: 7 Oct 21
Utility
Fused Heterocyclic Compounds As Ret Kinase Inhibitors
14 Apr 22
James F. BLAKE, Donghua DAI, Julia HAAS, Yutong JIANG, Dean KAHN, Gabrielle R. KOLAKOWSKI, Elizabeth A. MCFADDIN, Megan L. MCKENNEY, Andrew T. METCALF, David A. MORENO, Brett PRIGARO, Ginelle A. RAMANN, Li REN, Shane M. WALLS, Hailong ZHANG
Filed: 6 Sep 19
Utility
Glycoconjugation Processes and Compositions
31 Mar 22
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Jianxin Gu, Jin-hwan Kim, Avvari Krishna Prasad, Yu-ying Yang
Filed: 5 Aug 21
Utility
Cyclin Dependent Kinase Inhibitors
24 Mar 22
Ping Chen, Sujin Cho-Schultz, Judith Gail Deal, Gary Michael Gallego, Mehran Jalaie, Robert Steven Kania, Sajiv Krishnan Nair, Sacha Ninkovic, Suvi Tuula Marjukka Orr, Cynthia Louise Palmer
Filed: 7 Dec 21
Utility
Human Cytomegalovirus GB Polypeptide
24 Mar 22
The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB).
Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Filed: 17 Jun 21
Utility
Novel 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) Carbaldehyde Derivatives
24 Mar 22
Hui LI, Seiji NUKUI, Stephanie Anne SCALES, Min TENG, Chunfeng YIN
Filed: 1 Dec 21
Utility
Method of Treating Signs and Symptoms of Osteoarthritis
24 Mar 22
The present invention relates to the treatment of signs and symptoms of osteoarthritis with an anti-nerve growth factor (NGF) antibody.
Christine Ruth WEST, Mark Thomas BROWN
Filed: 27 Jan 20
Utility
Antibodies specific for epidermal growth factor receptor variant III and their uses
22 Mar 22
The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III).
Oi Kwan Wong, Joyce Ching Chou, Barbra Johnson Sasu
Filed: 17 Oct 18
Utility
Substituted PYRAZOLO[1,5-A]PYRIDINE Compounds As Inhibitors of FGFR Tyrosine Kinases
17 Mar 22
James F. Blake, David A. MORENO, Li REN, Tony P. TANG, Shane M. WALLS
Filed: 13 Dec 19
Utility
Dosing regimen of avelumab for the treatment of cancer
15 Mar 22
The present invention relates to dosing regimen of avelumab for the treatment of cancer.
Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
Filed: 5 Oct 17
Utility
Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
10 Mar 22
The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis.
Christine Ellen Bulawa, James Allan Fleming
Filed: 17 Dec 19
Utility
Cells with reduced inhibitor production and methods of use thereof
10 Mar 22
The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell.
Emily Ann DEUTSCHMAN, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, John Joseph SCARCELLI
Filed: 3 Dec 19
Utility
KRAS G12C inhibitors
8 Mar 22
The present invention relates to compounds that inhibit KRas G12C.
John P. Fischer, Jay Bradford Fell, James F. Blake, Ronald Jay Hinklin, Macedonio J. Mejia, Erik James Hicken, Mark Joseph Chicarelli, John J. Gaudino, Guy P. A. Vigers, Laurence E. Burgess, Matthew Arnold Marx, James Gail Christensen, Matthew Randolph Lee, Pavel Savechenkov, Henry J. Zecca, Tony P. Tang
Filed: 17 May 17
Utility
Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
8 Mar 22
Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.
Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
Filed: 14 Sep 20
Utility
Chimeric antigen receptors targeting epidermal growth factor receptor variant III
8 Mar 22
The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III).
Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu
Filed: 23 Jan 19
Utility
Nitrile-Containing Antiviral Compounds
3 Mar 22
Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Liuqing Wei, Qingyi Yang, Xiaojing Yang
Filed: 5 Aug 21
Utility
Unknown
1 Mar 22
In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof.
Robert G. K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
Filed: 7 Aug 19
Utility
Method for Predicting Response to Breast Cancer Therapeutic Agents and Method of Treatment of Breast Cancer
24 Feb 22
Methods for treating triple negative breast cancer with an androgen receptor inhibitor are provided, as well as methods for screening for the likelihood of the effectiveness of such treatment.
Amy Christian PETERSON, Hirdesh UPPAL
Filed: 10 Nov 21
Utility
Synthesis of PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES
24 Feb 22
Adam Ross Brown, Jean-Nicolas Desrosiers, Shengquan Duan, Joel Michael Hawkins, Cheryl Myers Hayward, Mark Thomas Maloney, Sebastien Monfette, Hahdi Hakimioun Perfect, Daniel William Widlicka
Filed: 23 Sep 19
Utility
Combinations for treatment of NASH/NAFLD and related diseases
22 Feb 22
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
William Paul Esler, Trenton Thomas Ross
Filed: 28 Aug 19